We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...
Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...
Die Zulassung ist ein neuer Katalysator für das internationale Wachstum von AtriCure AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im Bereich chirurgischer Behandlungen und Therapien...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.385 | -3.69925213675 | 37.44 | 38.34 | 35.63 | 435762 | 36.95766504 | CS |
4 | 6.885 | 23.6030167981 | 29.17 | 38.34 | 27.64 | 710728 | 32.980996 | CS |
12 | 12.085 | 50.4171881519 | 23.97 | 38.34 | 23.97 | 582095 | 29.69450498 | CS |
26 | 13.205 | 57.7899343545 | 22.85 | 38.34 | 18.94 | 724001 | 25.23206765 | CS |
52 | -2.145 | -5.61518324607 | 38.2 | 42.9999 | 18.94 | 707925 | 28.13254292 | CS |
156 | -41.775 | -53.674675575 | 77.83 | 79.625 | 18.94 | 431730 | 37.13686042 | CS |
260 | 7.945 | 28.2639630025 | 28.11 | 89.18 | 18.94 | 397479 | 42.34803063 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions